A 1-YEAR Retrospective Review of Ranibizumab for Naïve Nonsubfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (original) (raw)
Related papers
Ophthalmologica, 2011
Aim: Evaluation of safety and efficacy of intravitreal ranibizumab in the treatment of choroidal neovascularization (CNV) secondary to causes other than age-related macular degeneration (AMD) or pathological myopia (PM). Methods: Retrospective and multicentric analysis of 21 eyes with CNV. Nine eyes had angioid streaks, 5 inflammatory chorioretinal diseases, 3 central serous chorioretinopathy and 4 idiopathic CNV. Follow-ups lasted ≧3 months. Best-corrected visual acuity (BCVA), ocular coherence tomography (OCT) and fundus examination were assessed monthly. Results: Sixteen eyes (76%) completed 180 days of follow-up. Overall BCVA increased by +9.8 letters with treatment (p = 0.015). Visual acuity improvements ≧15 letters occurred in 43%. A significant reduction in OCT central thickness was observed. No cases of severe visual acuity loss, systemic or ocular side effects were registered. Conclusion: Short-term results of intravitreal ranibizumab for CNV unrelated to AMD or PM are enco...
Journal of Experimental and Clinical Medicine, 2013
Introduction Age-related macular degeneration (AMD) is the most common cause of legal blindness of 65 and over age group. Neovasculer AMD forms the 10 percent of the AMD but is responsible for 90 percent of the legal blindness (Ferris et al., 1984; Bird et al., 1995). In most of the cases, choroidal neovascularization (CNV) is located under the fovea (subfoveal) (Arias et al., 2009). At present, there are alternative treatment methods for subfoveal CNV such as photodynamic treatment (PDT) with verteporfin, intravitreal steroid or anti vascular endothelial growth factors (anti-VEGF; macugen, bevacizumab or ranibizumab) injection. Ranibizumab (Lucentis, Genentech Inc. South San Francisco, CA) is a recombinant, humanized monoclonal antibody fragment that inhibits all VEGF-A isoforms and was approved by the United States Food and Drug Administration for the treatment of neovascular AMD in June 2006 (Parravano et al., 2010). In our study, we assessed the effects of at least three intraocular ranibizumab injections, performed for the treatment of subfoveal choroidal neovascularization, on best corrected visual acuity and central macular thickness in patients who were classified by the component of lesion. 2. Materials and methods We reviewed retrospectively, the cards of patients with neovascular AMD treated with intravitreal ranibizumab injections at Ondokuz Mayıs University, Department of Ophthalmology, from Feb 2009 to June 2011. We included 89 eyes of 89 patients, who underwent three consecutive injections of ranibizumab at monthly intervals. At baseline, best corrected visual acuity (VA) was measured by Snellen card and was recorded in logMAR-logarithm of the minimum angle of resolution values. Flouroscein anjiography (FA, Carl Zeiss Meditec AG, Jena, Germany) was performed and CNV have been classified in classic, occult or mixt (classic+occult) type. Central macular thickness (CMT)
American Journal of Ophthalmology, 2009
PURPOSE: To assess the long-term efficacy of a variabledosing regimen with ranibizumab in the Prospective Optical Coherence Tomography (OCT) Imaging of Patients with Neovascular Age-Related Macular Degeneration (AMD) Treated with intraOcular Ranibizumab (PrONTO) Study, patients were followed for 2 years. • DESIGN: A 2-year prospective, uncontrolled, variabledosing regimen with intravitreal ranibizumab based on OCT. • METHODS: In this open-label, prospective, single-center, uncontrolled clinical study, AMD patients with neovascularization involving the central fovea and a central retinal thickness (CRT) of at least 300 m as measured by OCT were enrolled to receive 3 consecutive monthly intravitreal injections of ranibizumab (0.5 mg) [Lucentis; Genentech Inc, South San Francisco, California, USA]. During the first year, retreatment with ranibizumab was performed at each monthly visit if any criterion was fulfilled such as an increase in OCT-CRT of at least 100 m or a loss of 5 letters or more. During the second year, the retreatment criteria were amended to include retreatment if any qualitative increase in the amount of fluid was detected using OCT. • RESULTS: Forty patients were enrolled and 37 completed the 2-year study. At month 24, the mean visual acuity (VA) improved by 11.1 letters (P < .001) and the OCT-CRT decreased by 212 m (P < .001). VA improved by 15 letters or more in 43% of patients. These VA and OCT outcomes were achieved with an average of 9.9 injections over 24 months. • CONCLUSIONS: The PrONTO Study using an OCTguided variable-dosing regimen with intravitreal ranibizumab resulted in VA outcomes comparable with the outcomes from the phase III clinical studies, but fewer intravitreal injections were required. (Am J Ophthalmol 2009;148:43-58.
Clinical Interventions in Aging, 2014
To describe 1-year clinical results of intravitreal ranibizumab treatment in patients with choroidal neovascularization secondary to exudative age-related macular degeneration (AMD) and to evaluate whether early treatment is a predictive value for prognosis of the disease. Materials and methods: Clinical records were retrospectively reviewed of 104 eyes that underwent intravitreal ranibizumab therapy for exudative AMD. Patients were divided into two groups according to their symptom duration: group 1, ,1 month; and group 2, 1-3 months. After three monthly injections, patients were examined monthly, and subsequent injections were performed as needed. Results: There were 43 female (48.9%) and 45 males (51.1%). The follow-up time was 13.7±1.9 (12-19) months. The mean logarithm of minimum angle of resolution best-corrected visual acuity (BCVA) improved significantly, from 0.45±0.639 at baseline to 0.08±0.267 at 12 months in group 1, and from 1.06±0.687 at baseline to 0.75±0.563 at 12 months in group 2. The increase in BCVA was statistically significant in group 1 (P=0.009). The mean central retinal thickness (CRT) decreased significantly, from 355.13±119.93 µm at baseline to 250.85±45.48 µm at 12 months in group 1, and from 371.88±91.047 µm at baseline to 268.61±53.51 µm at 12 months in group 2. The decrease in CRT was statistically significant in group 1 (P=0.001). Conclusion: Intravitreal ranibizumab therapy was effective in significantly increasing mean BVCA and reducing CRT. Shorter duration of AMD, as measured by the subjective duration of visual symptoms, is associated with better visual outcome after treatment.
Canadian Journal of Ophthalmology Journal Canadien D Ophtalmologie, 2010
N RÉ SUMÉ Objective: To assess the effectiveness of intravitreal ranibizumab for neovascular age-related macular degeneration (AMD) in a tertiary care retina practice and compare these results with published efficacy data from randomized clinical trials. Design: Nonrandomized, consecutive, single-centre, retrospective chart review analysis. Participants: Ninety-four patients (95 eyes) with neovascular AMD. Methods: All treatment-naïve patients with neovascular AMD who received ranibizumab and for whom 1 year of followup was available were included in the analysis. The following information was gathered from each patient's chart: age, sex, ocular history, treated eye, duration of symptoms at presentation, subtype of choroidal neovascular membrane, Snellen visual acuity at each visit, number of injections, visits, and optical coherence tomography measurements. Results: Subjects had a mean age of 81 (SD 7.11) years. The mean number of injections was 5.1 (SD 2.85) with a mean of 9.4 (SD 2.27) visits in the 12-month period. Overall, there was a gain of 2.88 (SD 24.6) letters in all eyes, and a loss of 2.5 (SD 23.1) letters in patients who met the visual acuity inclusion criteria for the clinical trials. Of the patients who met the inclusion criteria, 75% lost fewer than 15 letters and 11% gained more than 15 letters. Conclusions: Visual outcomes in our study patients compared poorly with the clinical trials. Possibilities for the disparity include gaps in the number and frequency of follow-up visits, patient or doctor assessment fatigue, or gaps in optical coherence tomography utilization and the number of injections administered.
International journal of ophthalmology, 2018
To investigate the long-term visual and anatomical outcomes of patients who underwent intravitreal ranibizumab monotherapy to treat neovascular age-related macular degeneration (AMD) and followed-up for at least 2y. A total of 74 eyes of 74 patients who underwent ranibizumab monotherapy for neovascular AMD were included in this retrospective study. The average patient age was 72.1±6.5 (range, 57-85)y, the average follow-up time 46.2±13.1 (range, 24-75)mo, and the average number of visits 24.1±9.5 (range, 8-48). The mean number of injections in year 1 was 4.5, 1.6 in year 2, 0.9 in year 3, 0.4 on year 4, and 0.1 in the following years. Within the entire follow-up period, the mean number of injections was 7.6±4.4 (range, 2-21). The mean visual acuity was 48.1±15 (range, 15-76) letters at baseline and 45.7±19 (range, 7-75) at year 5. The mean central macular thickness was 303±78 (range, 178-552) µm at baseline and 251±51 (range, 138-359) µm at year 5. Scars developed in 47 (63.5%) eyes...
Ranibizumab for neovascular age-related macular degeneration
American Journal of Health-System Pharmacy, 2008
Ranibizumab -a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A -has been evaluated for the treatment of neovascular age-related macular degeneration.